Close Menu

NEW YORK — Biodesix said on Friday reported an over 200 percent jump in preliminary fourth quarter revenues on strong demand for its COVID-19 testing services.

For the three-month period ended Dec. 31, 2020 Biodesix expects revenues to be in the range of $25 million to $27 million compared with $8.3 million in the fourth quarter of 2019. Revenues from COVID-19 testing are anticipated to be between $20 million and $21 million in Q4, versus $5.5 million in the third quarter of the year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.